Announcing a new publication for Acta Materia Medica journal. New drug research and development (R&D) faces critical challenges such as drug resistance, ineffectiveness of single-target interventions, “undruggable” targets, long cycles, and high costs. This article analyzes five typical use cases to illustrate breakthrough strategies for addressing these issues.
Innovations include the identification of dual-target antibiotics (paenimicin) and phospholipid-targeting antifungals (mandimycin) that overcome microbial resistance via mining silent biosynthetic gene clusters; development of “molecular glue” compounds (D927 and BBO-10203) that regulate protein-protein interactions, thus addressing insulin resistance and tumor drug resistance; AI-driven discovery of the TNIK inhibitor rentosertib for reversing pulmonary fibrosis; use of protein interface remodeling to develop the KRAS G12D inhibitor zoldonrasib for “undruggable” targets; and repurposing of existing drug combinations (letrozole plus irinotecan), on the basis of multi-omics data for Alzheimer’s disease.
These use cases demonstrate how interdisciplinary technologies (e.g., AI and structural biology) and strategic innovations (multi-target design and drug repurposing) can drive a transformation from experience-driven to precision and intelligence-driven R&D, and provides a reference for meeting intractable clinical needs.
Read More: https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2025-0054
Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.
Submission Process
Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at https://mc04.manuscriptcentral.com/ammed
Queries about the journal can be sent to editorialoffice@amm-journal.org.
Please visit https://amm-journal.org/ to learn more about the journal.
Editorial Board: https://amm-journal.org/index.php/editorial-board/
There are no author submission or article processing fees.
Follow Acta Materia Medica on Twitter https://twitter.com/AMM_journal; Facebook (https://www.facebook.com/AMMjournal)
eISSN 2737-7946
Mei Wang, Kai Song and Haiyong Jia et al. How new drug R&D can solve intractable scientific problems and meet clinical needs: insights from analysis of typical use cases. Acta Materia Medica. 2026. Vol. 5(1):1-7. DOI: 10.15212/AMM-2025-0054